



Company name: JMS Co., Ltd.  
Name of representative: Ryuji Katsura, President and Representative Director  
(Securities code: 7702; Tokyo Stock Exchange)  
Contact: Jo Sueda, Executive Officer, Head of Corporate Affairs Division  
(Telephone: +81-82-243-5844)  
Contact site: <https://www.jms.cc/english/contact/index.html>

## Announcement Regarding Exclusive Sales Cooperation Agreement with Terumo Shanghai

HIROSHIMA, JAPAN – June 5, 2024 – JMS Co., Ltd., (President: Ryuji Katsura, hereinafter called “JMS”) today announced that its consolidated subsidiary company, JMS Dalian Medical Supply Co., Ltd. (Chairman: Michihiro Nagai, hereinafter called "JMS Dalian"), executed the exclusive sales cooperation agreement for the Chinese market with Terumo Medical (Shanghai) Co., Ltd. (Chairman: Sun Bao Lei, hereinafter called "Terumo Shanghai") regarding the heat exchanger for cardiopulmonary bypass which is produced by JMS Dalian.

### 1. The reason for executing this agreement

As the number of cardiac surgeries in China has increased in recent years, it is expected that the demand for safe, reliable, and high-quality cardiac surgery-related products will be expanded. Judging from this situation, with the utilization of JMS’ technology cultivated in Japan, JMS Dalian obtained the regulatory approval to manufacture and sell the heat exchanger for cardiopulmonary bypass in December 2023. Now JMS Dalian is preparing to launch the product.

Terumo Shanghai has a wide range of in-house product lines, including cardiovascular catheters and artificial lungs, and is developing and expanding their business by selling their products to medical institutions in China through their sales network.

Terumo Shanghai, which aims to provide new customer value, and JMS Dalian, which aims to expand the market for the heat exchanger for cardiopulmonary bypass, judged that they could contribute to medical safety in the Chinese market and business growth through the synergy of the business partnership between the both companies and executed the exclusive sales cooperation agreement for the Chinese market.

### 2. Future activities

Based on this agreement, JMS Dalian manufactures the myocardial protection circuits incorporating the heat exchanger for cardiopulmonary bypass to be sold to medical institutions in China through Terumo Shanghai’s sales network under the sales cooperation. Both companies aim to promote safe and reliable cardiac surgery-related products to medical professionals in the Chinese market while working together with each other and expand the market share by utilizing the synergy effects of the both companies’ products.

### 3. The outline of the partner

(1) Company Name	Terumo Medical (Shanghai) Co., Ltd.
(2) Location	Changning District, Shanghai, China
(3) Chairman	Sun Bao Lei
(4) Main business	Business related to import, export and sales of medical equipment and pharmaceuticals
(5) Establishment	December 26, 2013

---

4. Future prospect

The effects of this agreement are expected to be negligible on the consolidated financial results for the current fiscal year.

【Introduction of our products】



Heat exchanger for cardiopulmonary bypass

During cardiac surgery, myocardial protection way is used to stop the heart from beating, and temperature is controlled for the purpose of myocardial protection. JMS's heat exchanger for cardiopulmonary bypass is used as a medical device in such surgery and its feature is high heat exchange capacity and low priming volume.



Myocardial protection circuits incorporating the heat exchanger for cardiopulmonary bypass

During cardiac surgery, extracorporeal circulation is performed with a circuit which incorporates multiple medical devices. Cardiac protection circuits are also circuit products which incorporate a heat exchanger and multiple components. Pre-connecting helps to reduce the connection operation by medical professionals, to prevent misconnection, and to improve medical safety.

The forward-looking statements in this release are based on judgments made in accordance with currently available information and are subject to various potential risks and uncertainties, including major changes in social conditions. Please note that this information is current as of the date of publication and is subject to change in the future. Although it contains information on medical devices and pharmaceuticals, this information is intended for the press, shareholders, investors, and others, and is not intended to solicit customers or provide medical advice.

END